Citi raised the firm’s price target on Larimar Therapeutics to $10 from $4.50 and keeps a Buy rating on the shares. Positive topline data for Phase 2 50mg nomlabofusp trial appear to “check all the boxes” the firm was looking for in the readout, the analyst tells investors in a research note. The firm added that, while the data suggest nomla is active and capable of driving significant increases in frataxin, it continues to remain cautious ahead of seeing longer-term safety data.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LRMR:
- Larimar Therapeutics Announces Successful Phase 2 Nomlabofusp Study
- Larimar Therapeutics Reports Positive Phase 2 Results, Updates Investor Resources
- Larimar Therapeutics Phase 2 Success in Friedreich’s Ataxia Trial
- Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia
- William Blair biotech analyst to hold an analyst/industry conference call
